Hormone Refractory Prostate Cancer - by Associate Professor Gavin Marx - 28 November 2011
808 بار بازدید -
12 سال پیش
-
Associate Professor Gavin Marx from
Associate Professor Gavin Marx from the Sydney Haematology and Oncology Clinic, SAN Clinic, spoke to the SAN PCSG on 28 November 2011 to update the progress of critical clinical trials and research.
In Australia approximately 20,000 men are diagnosed each year with prostate cancer. Of these, 3,300 will die of their disease, some as young as 45.
In the last six to seven years, there has been some progress made in the treatment of Hormone Refractory Prostate Cancer, (HRPC), otherwise known as Castrate Refractory Prostate Cancer (CRPC), and in 2010 three new large positive randomised trials were reported. Each of these three trials used a different approach: cytotoxic chemotherapy, hormonal manipulation and immune therapy.
Dr Marx said that prostate cancer trials were difficult trials to conduct because of the complexity of the disease and the difficulty in defining reproducible endpoints. He said that HRPC is a heterogeneous (ie., diverse in content or character) disease. PSA (prostate specific antigen) progress provides a reasonable surrogate marker, but it is not absolute and it has limitations.
There has been a significant number of drugs available for clinical trials, amongst them Taxotere. Dr Marx speaks about the two landmark studies which have extended the lives of patients using Taxotere. He also speaks about targeted therapies: Anti-Angiogenic Agents (angiogenesis is the physiological process involving the growth of new blood vessels from pre-existing vessels). This is a normal and vital process in growth and development as well as in wound healing. It is also a fundamental step in the transition of tumours from a dormant state to a malignant one.
Further into the presentation Dr Marx speaks about Cabazitaxel which is a second-generation semi-synthetic taxane that inhibits microtubule depolymerisation (the conversion of a polymer which is a large molecule composed of repeating structural units) into its component monomers (one part) leading to cell cycle arrest and cell death. He also explains, comprehensively, the use of Abiraterone Acetate highlighting the randomised trial presented at a meeting of the European Society of Medical Oncology which demonstrated significant benefits.
Although a subject with many unfamiliar drug names and cancer terminologies Dr Marx fills you with confidence in his lay explanations and expansion of advice on what's best for his patients as an important priority with the individualised treatment pathways. Ongoing patient enrolment in clinical trials is important to try to further improve the outcomes of patients with CRPC.
In Australia approximately 20,000 men are diagnosed each year with prostate cancer. Of these, 3,300 will die of their disease, some as young as 45.
In the last six to seven years, there has been some progress made in the treatment of Hormone Refractory Prostate Cancer, (HRPC), otherwise known as Castrate Refractory Prostate Cancer (CRPC), and in 2010 three new large positive randomised trials were reported. Each of these three trials used a different approach: cytotoxic chemotherapy, hormonal manipulation and immune therapy.
Dr Marx said that prostate cancer trials were difficult trials to conduct because of the complexity of the disease and the difficulty in defining reproducible endpoints. He said that HRPC is a heterogeneous (ie., diverse in content or character) disease. PSA (prostate specific antigen) progress provides a reasonable surrogate marker, but it is not absolute and it has limitations.
There has been a significant number of drugs available for clinical trials, amongst them Taxotere. Dr Marx speaks about the two landmark studies which have extended the lives of patients using Taxotere. He also speaks about targeted therapies: Anti-Angiogenic Agents (angiogenesis is the physiological process involving the growth of new blood vessels from pre-existing vessels). This is a normal and vital process in growth and development as well as in wound healing. It is also a fundamental step in the transition of tumours from a dormant state to a malignant one.
Further into the presentation Dr Marx speaks about Cabazitaxel which is a second-generation semi-synthetic taxane that inhibits microtubule depolymerisation (the conversion of a polymer which is a large molecule composed of repeating structural units) into its component monomers (one part) leading to cell cycle arrest and cell death. He also explains, comprehensively, the use of Abiraterone Acetate highlighting the randomised trial presented at a meeting of the European Society of Medical Oncology which demonstrated significant benefits.
Although a subject with many unfamiliar drug names and cancer terminologies Dr Marx fills you with confidence in his lay explanations and expansion of advice on what's best for his patients as an important priority with the individualised treatment pathways. Ongoing patient enrolment in clinical trials is important to try to further improve the outcomes of patients with CRPC.
12 سال پیش
در تاریخ 1391/03/31 منتشر شده
است.
808
بـار بازدید شده